Evoke Wealth’s PMV Pharmaceuticals PMVP Stock Holding History

Evoke Wealth’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-133,122	Closed	-$165K	–	481
2026 Q1	$165K	Hold	133,122	–	–	﹤0.01%	685
2025 Q4	$166K	Hold	133,122	–	–	﹤0.01%	650
2025 Q3	$186K	Hold	133,122	–	–	﹤0.01%	620
2025 Q2	$141K	Hold	133,122	–	–	﹤0.01%	576
2025 Q1	$145K	Hold	133,122	–	–	﹤0.01%	435
2024 Q4	$201K	Hold	133,122	–	–	0.01%	410
2024 Q3	$198K	Buy	133,122 +69,889	+111%	+$108K	0.01%	397
2024 Q2	$102K	Buy	+63,233	New	+$114K	0.12%	95
2023 Q1	–	Sell	-133,122	Closed	-$1.16M	–	370
2022 Q4	$1.16M	Hold	133,122	–	–	0.04%	149
2022 Q3	$1.58M	Hold	133,122	–	–	0.06%	115
2022 Q2	$1.9M	Buy	133,122 +101,208	+317%	+$1.47M	0.07%	112
2022 Q1	$664K	Hold	31,914	–	–	0.02%	205
2021 Q4	$737K	Buy	+31,914	New	+$771K	0.02%	206
2021 Q3	–	Sell	-3,403	Closed	-$116K	–	1202
2021 Q2	$116K	Buy	+3,403	New	+$114K	﹤0.01%	414

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Evoke Wealth's PMVP Position: Q2 2026 in Review

Evoke Wealth sold out of PMV Pharmaceuticals (PMVP) in Q2 2026, closing a stake of 133,122 shares — an estimated $165K sold.

Evoke Wealth first reported a position in PMVP in Q2 2021 and held it in 14 quarters. The position peaked at $1.9M in Q2 2022. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

Evoke Wealth reported no remaining PMV Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Evoke Wealth sold 133,122 PMV Pharmaceuticals shares in Q2 2026, an estimated $165K.
Evoke Wealth first reported a position in PMV Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Evoke Wealth's PMV Pharmaceuticals position peaked at $1.9M in Q2 2022.
64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.